These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 10533189

  • 1. Can bone marrow scintigraphy predict platelet toxicity after treatment with 186Re-HEDP?
    de Klerk JM, Zonnenberg BA, van Het Schip AD, van Dijk A, Huiskes AW, van Rijk PP.
    Nucl Med Commun; 1999 Sep; 20(9):833-6. PubMed ID: 10533189
    [Abstract] [Full Text] [Related]

  • 2. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts.
    de Klerk JM, van Dieren EB, van het Schip AD, Hoekstra A, Zonnenberg BA, van Dijk A, Rutgers DH, Blijham GH, van Rijk PP.
    J Nucl Med; 1996 Jan; 37(1):38-41. PubMed ID: 8543998
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations.
    de Klerk JM, van het Schip AD, Zonnenberg BA, van Dijk A, Stokkel MP, Han SH, Blijham GH, van Rijk PP.
    J Nucl Med; 1994 Sep; 35(9):1423-8. PubMed ID: 8071686
    [Abstract] [Full Text] [Related]

  • 4. A model-based method for the prediction of whole-body absorbed dose and bone marrow toxicity for 186Re-HEDP treatment of skeletal metastases from prostate cancer.
    Buffa FM, Flux GD, Guy MJ, O'Sullivan JM, McCready VR, Chittenden SJ, Dearnaley DP.
    Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1114-24. PubMed ID: 12761596
    [Abstract] [Full Text] [Related]

  • 5. Systemic radionuclide therapy in pain palliation.
    Liepe K, Runge R, Kotzerke J.
    Am J Hosp Palliat Care; 2005 Aug; 22(6):457-64. PubMed ID: 16323716
    [Abstract] [Full Text] [Related]

  • 6. Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer.
    de Klerk JM, Zonnenberg BA, van het Schip AD, van Dijk A, Han SH, Quirijnen JM, Blijham GH, van Rijk PP.
    Eur J Nucl Med; 1994 Oct; 21(10):1114-20. PubMed ID: 7530199
    [Abstract] [Full Text] [Related]

  • 7. 186Re-HEDP for metastatic bone pain in breast cancer patients.
    Lam MG, de Klerk JM, van Rijk PP.
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S162-70. PubMed ID: 15118846
    [Abstract] [Full Text] [Related]

  • 8. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases.
    Liepe K, Kotzerke J.
    Nucl Med Commun; 2007 Aug; 28(8):623-30. PubMed ID: 17625384
    [Abstract] [Full Text] [Related]

  • 9. Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP.
    De Klerk JM, Zonnenberg BA, Blijham GH, Van Het Schip AD, Hoekstra A, Han SH, Quirijnen JM, Van Dijk A, Van Rijk PP.
    Anticancer Res; 1997 Aug; 17(3B):1773-7. PubMed ID: 9179233
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer.
    Kolesnikov-Gauthier H, Carpentier P, Depreux P, Vennin P, Caty A, Sulman C.
    J Nucl Med; 2000 Oct; 41(10):1689-94. PubMed ID: 11037999
    [Abstract] [Full Text] [Related]

  • 11. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer.
    Dafermou A, Colamussi P, Giganti M, Cittanti C, Bestagno M, Piffanelli A.
    Eur J Nucl Med; 2001 Jul; 28(7):788-98. PubMed ID: 11504074
    [Abstract] [Full Text] [Related]

  • 12. Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients.
    Sciuto R, Festa A, Pasqualoni R, Semprebene A, Rea S, Bergomi S, Maini CL.
    Breast Cancer Res Treat; 2001 Mar; 66(2):101-9. PubMed ID: 11437096
    [Abstract] [Full Text] [Related]

  • 13. Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer.
    de Klerk JM, van het Schip AD, Zonnenberg BA, van Dijk A, Quirijnen JM, Blijham GH, van Rijk PP.
    J Nucl Med; 1996 Feb; 37(2):244-9. PubMed ID: 8667053
    [Abstract] [Full Text] [Related]

  • 14. [Clinical experience with rhenium-188 HEDP therapy for metastatic bone pain].
    Róka R, Séra T, Pajor L, Thurzó L, Láng J, Csernay L, Pávics L.
    Orv Hetil; 2000 May 07; 141(19):1019-23. PubMed ID: 10846424
    [Abstract] [Full Text] [Related]

  • 15. Myeloprotective effects of different amifostine regimens in rabbits undergoing high-dose treatment with 186rhenium-(tin)1,1- hydroxyethylidene diphosphonate (186Re-HEDP).
    Brenner W, Kampen WU, Brümmer C, Von Forstner C, Zuhayra M, Muhle C, Czech N, Henze E.
    Cancer Biother Radiopharm; 2003 Dec 07; 18(6):887-93. PubMed ID: 14969601
    [Abstract] [Full Text] [Related]

  • 16. Transient cranial neuropathy in prostatic cancer with bone metastases after rhenium-186-HEDP treatment.
    de Klerk JM, Zonnenberg BA, Krouwer HG, Blijham GH, van Dijk A, van het Schip AD, van Die J, van Rijk PP.
    J Nucl Med; 1996 Mar 07; 37(3):465-7. PubMed ID: 8772646
    [Abstract] [Full Text] [Related]

  • 17. Skeletal uptake and soft-tissue retention of 186Re-HEDP and 153Sm-EDTMP in patients with metastatic bone disease.
    Brenner W, Kampen WU, Kampen AM, Henze E.
    J Nucl Med; 2001 Feb 07; 42(2):230-6. PubMed ID: 11216521
    [Abstract] [Full Text] [Related]

  • 18. Palliative analgesic effect of Re-186 HEDP in various cancer patients with bone metastases.
    Küçük NO, Ibiş E, Aras G, Baltaci S, Ozalp G, Bedük Y, Canakci N, Soylu A.
    Ann Nucl Med; 2000 Aug 07; 14(4):239-45. PubMed ID: 11023023
    [Abstract] [Full Text] [Related]

  • 19. [Palliative treatment for pain in osseous metastasized prostatic carcinoma with osteotropic rhenium-186 hydroxyethylidene diphosphonate (HEDP)].
    Holle LH, Humke U, Trampert L, Ziegler M, Kirsch CM, Oberhausen E.
    Urologe A; 1997 Nov 07; 36(6):540-7. PubMed ID: 9487590
    [Abstract] [Full Text] [Related]

  • 20. Radiation dose estimates of 186Re-hydroxyethylidene diphosphonate for palliation of metastatic osseous lesions: an animal model study.
    van Aswegen A, Roodt A, Marais J, Botha JM, Naudé H, Lötter MG, Goedhals L, Doman MJ, Otto AC.
    Nucl Med Commun; 1997 Jun 07; 18(6):582-8. PubMed ID: 9259533
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.